Drug discovery and product research leveraging the clinical platform, and the creation of new sources of revenue
First written in FY2025. 11 of 13 entries say "Advanced", first in FY2026-H1. Latest entry: FY2026.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Centered on the WOLVES HAND Institute for Advanced Veterinary Medicine, the Group advanced collaboration with universities, research institutions, medical institutions and external companies, and worked to strengthen its research and development structure in advanced medicine, regenerative medicine, drug discovery, medical engineering and AI medical devices.」
The Group is advancing a collaboration structure centered on the institute for research and development that leverages its clinical base, with applications in medical devices, biomaterials, drug discovery and other areas. - FY2026-H1AdvancedAnnual report
「Asuka Medical’s laser scalpel is currently a key device in photoimmunotherapy, which we are currently conducting clinical trials for, and we believe that Asuka Medical’s nationwide veterinary hospital network will contribute to our future growth strategy, including M&A and product sales. We therefore decided to acquire the shares with the aim of making it a wholly owned subsidiary, further strengthening collaboration and accelerating our growth strategy.」
The acquisition of Asuka Medical as a wholly owned subsidiary brings in laser medical equipment and a nationwide veterinary hospital network, giving concrete form to product and research development based on the clinical platform and the creation of new revenue sources. - FY2025First statedAnnual report
「We are strengthening research and development activities for drugs and products related to veterinary medicine by leveraging our clinical platform, and working to create new revenue sources outside clinical care in veterinary medicine. We have entered into joint research agreements and other arrangements as shown below.」
Joint research is under way in areas including supplements, cancer recurrence prevention, biopharmaceuticals, liquid biopsies, stem cells and laser treatment.